Intratendinous Injection of Mesenchymal Stem Cells for the Treatment of Rotator Cuff Disease: A 2-Year Follow-Up Study.
To assess the mid-term safety and efficacy of an intratendinous injection of autologous adipose tissue derived MSCs (AD MSCs) for rotator cuff disease at 2-year follow-up. The first part of the study consists of 3 dose-escalation groups; the low- (1.0x107 cells), mid- 5.0x107), and high-dose (1.0x108) groups with 3 patients each for the evaluation of the safety. The second part was planned to include nine patients receiving the high-dose for the evaluation of the exploratory efficacy. Clinical outcomes were assessed according to pain, range of motion, muscle strength, functional scores, overall satisfaction and function, and the presence of failure. Structural outcome included changes of volume of tendon defects measured using MRI. Nineteen patients (9 for the first study, and 10 for the second) with a partial-thickness rotator cuff tear were enrolled. There were no treatment-related adverse events at minimum 2-year follow-up. Intratendinous injection of AD MSCs reduced shoulder pain by approximately 90% at 1 and 2 years in the mid- and high-dose groups. The strengths of the supraspinatus, infraspinatus, and teres minor significantly increased greater than 50% at 2 years in the high dose group. Shoulder function measured with the six commonly used scores improved for up to 2 years in all dose groups. The structural outcomes evaluated with MRI showed volume of the bursal-side defect in the high-dose group nearly disappeared from 1 year, and did not recur up to 2 years. There were no failures defined as occurrence of any kind of shoulder surgery or the return of the SPADI score back to preinjection level during the follow-up. This study demonstrated continued safety and efficacy of intratendinous injection of AD MSCs of for the treatment of a partial-thickness rotator cuff tear over 2 years through regeneration of tendon defect.